Topic: Immunotherapeutic Approaches for Treatment of Brain Tumors

Download All Articles

A special issue of Neuroimmunology and Neuroinflammation  (Print ISSN:2347-8659; Online ISSN:2349-6142).

Deadline for manuscript submissions: 31 Jul 2018

Share This Special Issue

Guest Editor(s)

  • Dr. Terry Lichtor, MD, PhD
    Associate Professor, Neurological Surgery, Rush University, Rush Medical College, Rush University Medical Center in Chicago, Illinois, USA.

    Website | E-mail

Special Issue Introduction:

Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. One emerging strategy in the treatment of tumors involves stimulation of an immunologic response against the neoplastic cells. Tumor cells may evade immune responses by losing expression of antigens or major histocompatiblity complex (MHC) molecules or by producing immunosuppressive cytokines. A variety of strategies have been used to increase the immunogenetic properties of vaccine therapies for brain tumors. The immune response can be augmented by genetic modification of tumor cells to secrete cytokines including IL-2, GM-CSF and interferon-γ. Alternatively, one can genetically modify the tumor cells to express co-stimulatory molecules such as B7.
Modification of neoplastic cells taken directly from tumor-bearing patients may be difficult. An alternative cell type that can be used for therapeutic immunizations is the dendritic cell (DC), which is a specialized antigen presenting cell. Pre-clinical studies have indicated that immunization with DC pulsed with tumor cell antigens can stimulate a cytotoxic T cell response that is tumor-specific and that engenders protective immunity against CNS tumors. Another strategy is to transfect genomic DNA from the malignant cells into a fibroblast cell line which results in stable integration and expression of the transferred DNA. Immunization of tumor-bearing mice with the DNA-based vaccine results in the induction of cell mediated immunity directed toward the type of tumor from which the DNA was obtained along with prolongation of survival.
The ultimate goal of cancer therapy is the elimination of every remaining tumor cell from the patient. It is unlikely that a single form of therapy is capable of achieving this goal. However, immunotherapy in combination with surgery, radiation therapy and chemotherapy will likely find a place as a new and important means of treatment for patients with brain tumors. For this special issue papers are being solicited that explore the potential of different immunotherapeutic strategies for the treatment of brain tumors along with related aspects of tumor immunotherapy.


Immunotherapy, brain tumors, tumor vaccine, immune suppression, tumor growth, gene therapy

Submission Information:

For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Jul 2018
Contacts: Nancy Ding, Assistant Editor,

Published Articles Download All Articles
  • The novel-molecule T11TS facilitated arousal of glioma-mediated dormancy of bone-marrow hematopoietic stem-cells

    Somnath Mondal , Ankur Datta , Iman Hazra , Sk Md Omar Faruk , Saibal Moitra , Suhnrita Chaudhuri , Lakshyajeet Nath , Prasanta Kumar Das , Anjan Kumar Basu , Santanu Kumar Tripathi , Swapna Chaudhuri
    Aim: T11TS, a potent anti-gliomagenic glycoprotein, stimulates both peripheral and intracranial immune response. The status of bone marrow hematopoietic stem cells (BMHSCs), the cradle of regeneration of all blood cells, during gliomagenic global immune devastations has not yet been investigated. Therefore, we aimed to delineate the effects of T11TS on immature and mature compartments of hematopoietic machinery. Methods: Flowcytometric analysis of cultured BMHSCs was evaluated for assesing the expression pattern of early hematopoietic stem cells (HSCs) markers such as CD34+, Sca-1+, c-kit+... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:34. | doi:10.20517/2347-8659.2018.13
    Published on: 30 Aug 2018  | Viewed:217  | Downloaded:12
    +HTML| PDF
  • Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy

    Jiaxin Niu , Junle Zhou , Sara Lindebak , Fade Mahmoud
    Brain metastasis (BM) is very common in advanced non-small cell lung cancer (NSCLC) patients. The development of BM remains a serious complication associated with significant morbidity and mortality. The traditional approach has been largely focusing on local therapy with surgery and/or radiation. New approaches to treat BM in NSCLC are urgently needed to offer safe and effective therapy as well as to preserve neurocognitive function. There has been significant progress in development of systemic therapies to treat advanced NSCLC in recent years. Targeted therapy has been gradually... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:32. | doi:10.20517/2347-8659.2018.39
    Published on: 23 Aug 2018  | Viewed:383  | Downloaded:61
    +HTML| PDF
  • Immunotherapy for pediatric brain tumors

    Daniel B. Landi , Eric M. Thompson , David M. Ashley
    Immunotherapy, while effective against lymphoid cancers and some solid tumors, has shown less benefit against pediatric brain tumors. Tumor heterogeneity, a suppressive immune microenvironment, and the blood-brain barrier have the potential to diminish any immune-based approach and limit efficacy. More importantly, most pediatric brain tumors are immunologically quiescent, stemming from a low mutational burden. This review focuses on innate vs. adaptive immunotherapeutic approaches and describes how the immunologic context of pediatric brain tumors can help identify well-suited... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:29. | doi:10.20517/2347-8659.2018.35
    Published on: 23 Jul 2018  | Viewed:1500  | Downloaded:125
    +HTML| PDF
  • Photodynamic therapy mediated immune therapy of brain tumors

    Henry Hirschberg , Kristian Berg , Qian Peng
    Photodynamic therapy of tumors requires the topical, systemic or oral administration of a photosensitizing compound,illumination of the tumor area by light of a specific wavelength and the presence of oxygen. Light activation of the photosensitizer transfers energy to molecular oxygen creating singlet oxygen, a highly reactive and toxic species that rapidly reacts with cellular components causing oxidative damage, ultimately leading to cell death. Tumor destruction caused by photodynamic therapy is not only a result of direct tumor cell toxicity via the generation of reactive oxygen species... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:27. | doi:10.20517/2347-8659.2018.31
    Published on: 10 Jul 2018  | Viewed:1097  | Downloaded:63
    +HTML| PDF
  • Classification of brain tumor using devernay sub-pixel edge detection and k-nearest neighbours methodology

    Ayush Arora , Ritesh Kumar , Shubham Tiwari , Mysore Shwetha , Selvam Venkatesan , Ramesh Babu
    Any disease can be treated only once it is imaged, detected and classified. This paper proposes a set of algorithms for classification of a brain tumor with better accuracy and efficiency. The proposal uses a JPEG format of the DICOM image fed into three stages namely pre-processing, segmentation using sub-pixel edge detection method and using the nearest neighbor methodology for the detection and differentiation of benign and malignant tumors. Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:26. | doi:10.20517/2347-8659.2018.11
    Published on: 19 Jun 2018  | Viewed:679  | Downloaded:29
    +HTML| PDF
  • A concise review of immunotherapy for glioblastoma

    Omer Sager , Ferrat Dincoglan , Selcuk Demiral , Bora Uysal , Hakan Gamsiz , Bahar Dirican , Murat Beyzadeoglu
    Glioblastoma (GB) is the most common and aggressive form of primary brain tumors in adults with a universally poor prognosis despite multimodal management including surgery, chemotherapy and radiation therapy. Among the novel therapeutic strategies, immunotherapy deserves particular attention with its potential to evoke biologic response and harness the host immune system. Considerable success achieved for other tumors has elicited great enthusiasm and prompted research on immunotherapy for GB. While the central nervous system has traditionally been thought of as an immune-privileged site,... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:25. | doi:10.20517/2347-8659.2018.12
    Published on: 15 Jun 2018  | Viewed:670  | Downloaded:111
    +HTML| PDF
Neuroimmunology and Neuroinflammation ISSN 2349-6142 (Online), ISSN 2347-8659 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.